Passa al contenuto
Merck
  • Expression of cytoskeleton and energetic metabolism-related proteins at human abdominal aortic aneurysm sites.

Expression of cytoskeleton and energetic metabolism-related proteins at human abdominal aortic aneurysm sites.

Journal of vascular surgery (2012-01-10)
Javier Modrego, Antonio J López-Farré, Isaac Martínez-López, Miguel Muela, Carlos Macaya, Javier Serrano, Guillermo Moñux
ABSTRACT

The purpose of this study was to evaluate the expression of proteins related to cytoskeleton and energetic metabolism at abdominal aortic aneurysm (AAA) sites using proteomics. Several remodeling-related mechanisms have been associated with AAA formation but less is known about the expression of proteins associated with cytoskeleton and energetic metabolism in AAAs. AAA samples (6.73 ± 0.40 cm size) were obtained from 13 patients during elective aneurysm repair. Control abdominal aortic samples were obtained from 12 organ donors. Proteins were analyzed using two-dimensional electrophoresis and mass spectrometry. The expression of filamin was increased in the AAA site compared to control abdominal aortic samples while microfibril-associated glycoprotein-4 isotype 1, annexin A5 isotype 1, and annexin A2 were reduced compared with control abdominal aortic samples. Reduction in expression level of energetic metabolism-associated proteins such as triosephosphate isomerase, glyceraldehyde 3-phosphate dehydrogenase, and cytosolic aldehyde dehydrogenase was also observed in AAAs compared to controls. Reduction of triosephosphate isomerase expression was also observed by Western blot, which was accompanied by diminished triosephosphate isomerase activity. At the AAA site, pyruvate dehydrogenase expression was reduced and the content of both lactate and pyruvate was increased with respect to controls without changes in lactate dehydrogenase activity. The present results suggest that an anaerobic metabolic state may be favored further to reduce the expression of cytoskeleton-related proteins. The better knowledge of molecular mechanism involved in AAAs may favor development of new clinical strategies.

MATERIALI
N° Catalogo
Marchio
Descrizione del prodotto

Sigma-Aldrich
β-nicotinamide adenina dinucleotide, ridotta, ≥97% (HPLC)
Sigma-Aldrich
D-Fructose 1,6-bisphosphate tetra(cyclohexylammonium) salt, ≥95% anhydrous basis (enzymatic)